BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 20922561)

  • 1. IVIg attenuates TLR-9 activation in B cells from SLE patients.
    Kessel A; Peri R; Haj T; Snir A; Slobodin G; Sabo E; Rosner I; Shoenfeld Y; Toubi E
    J Clin Immunol; 2011 Feb; 31(1):30-8. PubMed ID: 20922561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-21 is increased in active systemic lupus erythematosus patients and contributes to the generation of plasma B cells.
    Nakou M; Papadimitraki ED; Fanouriakis A; Bertsias GK; Choulaki C; Goulidaki N; Sidiropoulos P; Boumpas DT
    Clin Exp Rheumatol; 2013; 31(2):172-9. PubMed ID: 23137515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B cell-activating factor enhances interleukin-6 and interleukin-10 production by ODN-activated human B cells.
    Yehudai D; Snir A; Peri R; Halasz K; Haj T; Odeh M; Kessel A
    Scand J Immunol; 2012 Oct; 76(4):371-7. PubMed ID: 22725135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to ODN-CpG by B Cells from patients with systemic lupus erythematosus correlates with disease activity.
    Zorro S; Arias M; Riaño F; Paris S; Ramírez LA; Uribe O; García LF; Vásquez G
    Lupus; 2009 Jul; 18(8):718-26. PubMed ID: 19502268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process.
    Papadimitraki ED; Choulaki C; Koutala E; Bertsias G; Tsatsanis C; Gergianaki I; Raptopoulou A; Kritikos HD; Mamalaki C; Sidiropoulos P; Boumpas DT
    Arthritis Rheum; 2006 Nov; 54(11):3601-11. PubMed ID: 17075805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA.
    Wagner M; Poeck H; Jahrsdoerfer B; Rothenfusser S; Prell D; Bohle B; Tuma E; Giese T; Ellwart JW; Endres S; Hartmann G
    J Immunol; 2004 Jan; 172(2):954-63. PubMed ID: 14707068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production.
    Lenert P; Brummel R; Field EH; Ashman RF
    J Clin Immunol; 2005 Jan; 25(1):29-40. PubMed ID: 15742155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD40-activated B cells from patients with systemic lupus erythematosus can be modulated by therapeutic immunoglobulins in vitro.
    Néron S; Boire G; Dussault N; Racine C; de Brum-Fernandes AJ; Côté S; Jacques A
    Arch Immunol Ther Exp (Warsz); 2009; 57(6):447-58. PubMed ID: 19866343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of peripheral blood mononuclear cells from lupus patients to stimulation by CpG oligodeoxynucleotides.
    Zeuner RA; Klinman DM; Illei G; Yarboro C; Ishii KJ; Gursel M; Verthelyi D
    Rheumatology (Oxford); 2003 Apr; 42(4):563-9. PubMed ID: 12649404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus.
    Nakano S; Morimoto S; Suzuki J; Nozawa K; Amano H; Tokano Y; Takasaki Y
    Rheumatology (Oxford); 2008 Feb; 47(2):145-9. PubMed ID: 18160420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of marginal zone B cells from lupus mice with type A(D) CpG-oligodeoxynucleotides.
    Brummel R; Lenert P
    J Immunol; 2005 Feb; 174(4):2429-34. PubMed ID: 15699180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IFN-alpha amplifies human naive B cell TLR-9-mediated activation and Ig production.
    Giordani L; Sanchez M; Libri I; Quaranta MG; Mattioli B; Viora M
    J Leukoc Biol; 2009 Aug; 86(2):261-71. PubMed ID: 19401392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR9 responses of B cells are repressed by intravenous immunoglobulin through the recruitment of phosphatase.
    Séité JF; Guerrier T; Cornec D; Jamin C; Youinou P; Hillion S
    J Autoimmun; 2011 Nov; 37(3):190-7. PubMed ID: 21689906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with a toll-like receptor inhibitory GpG oligonucleotide delays and attenuates lupus nephritis in NZB/W mice.
    Graham KL; Lee LY; Higgins JP; Steinman L; Utz PJ; Ho PP
    Autoimmunity; 2010 Mar; 43(2):140-55. PubMed ID: 19845477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG-oligodeoxynucleotides stimulate immunoglobulin A secretion in intestinal mucosal B cells.
    Blaas SH; Stieber-Gunckel M; Falk W; Obermeier F; Rogler G
    Clin Exp Immunol; 2009 Mar; 155(3):534-40. PubMed ID: 19220839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered IL-10 and TNF-α production in peripheral blood mononuclear cells of systemic lupus erythematosus patients after Toll-like receptor 2, 4, or 9 activation.
    Tsao JT; Hsieh SC; Chiang BL; Yu CL; Lin SC
    Clin Exp Med; 2012 Sep; 12(3):153-8. PubMed ID: 22057691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus mice.
    Brummel R; Roberts TL; Stacey KJ; Lenert P
    Eur J Immunol; 2006 Jul; 36(7):1951-62. PubMed ID: 16791898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired TLR9 responses in B cells from patients with systemic lupus erythematosus.
    Gies V; Schickel JN; Jung S; Joublin A; Glauzy S; Knapp AM; Soley A; Poindron V; Guffroy A; Choi JY; Gottenberg JE; Anolik JH; Martin T; Soulas-Sprauel P; Meffre E; Korganow AS
    JCI Insight; 2018 Mar; 3(5):. PubMed ID: 29515028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased frequency of immunoglobulin (Ig)A-secreting cells following Toll-like receptor (TLR)-9 engagement in patients with Kawasaki disease.
    Giordani L; Quaranta MG; Marchesi A; Straface E; Pietraforte D; Villani A; Malorni W; Del Principe D; Viora M
    Clin Exp Immunol; 2011 Mar; 163(3):346-53. PubMed ID: 21175593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-like receptor 9 activation enhances B cell activating factor and interleukin-21 induced anti-proteinase 3 autoantibody production in vitro.
    Lepse N; Land J; Rutgers A; Kallenberg CG; Stegeman CA; Abdulahad WH; Heeringa P
    Rheumatology (Oxford); 2016 Jan; 55(1):162-72. PubMed ID: 26320128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.